Cathepsin L induces proangiogenic changes in human omental microvascular endothelial cells via activation of the ERK1/2 pathway.
CONCLUSION: These data suggest that CathL acts as an extracellular ligand and plays an important pro-angiogenic, and thus pro-metastatic, role during EOC metastasis to the omentum, by activating the omental microvasculature, and thus can potentially be targeted therapeutically in the future. PMID: 30173647 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 31, 2018 Category: Cancer & Oncology Authors: Pranjol MZI, Gutowski NJ, Hannemann M, Whatmore JL Tags: Curr Cancer Drug Targets Source Type: research

The evaluation of animal models in the development of anticancer agents : from preclinical to clinical tests.
CONCLUSION: these information helps smart select the suitable predictive model for anti-cancer drugs with the different mechanisms and emphasized the pharmaceutical challenges behind and ahead. PMID: 30117392 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 16, 2018 Category: Cancer & Oncology Authors: Wang J, Dong H, Peng H, Liu J, Zheng N, Xie X, Jia L Tags: Curr Cancer Drug Targets Source Type: research

Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein-Protein Interactions in Cancer: Mechanistic View.
Abstract Protein-protein interactions (PPIs) drive major signalling cascades and play critical role in cell proliferation, apoptosis, angiogenesis and trafficking. Deregulated PPIs are implicated in multiple malignancies and represent the critical targets for treating cancer. Herein we discuss the key protein-protein interacting domains implicated in cancer notably PDZ, SH2, SH3, LIM, PTB, SAM and PH. These domains are present in numerous enzymes/kinases, growth factors, transcription factors, adaptor proteins, receptors and scaffolding proteins and thus represent essential sites for targeting cancer. This review ...
Source: Current Cancer Drug Targets - August 2, 2018 Category: Cancer & Oncology Authors: Dar KB, Bhat AH, Amin S, Anjum S, Reshi BA, Zargar MA, Masood A, Ganie SA Tags: Curr Cancer Drug Targets Source Type: research

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.
Abstract Prostate cancer (PCa) is the most frequent cancer in men. The evolution from local PCa to castration-resistant PCa, an end-stage of disease, is often associated with changes in genes such as p53, androgen receptor, PTEN, and ETS gene fusion products. Evidence is accumulating that repurposing of metformin (MET) and valproic acid (VPA) either when used alone, or in combination, with another therapy, could potentially play a role in slowing down PCa progression. This review provides an overview of the application of MET and VPA, both alone and in combination with other drugs for PCa treatment, correlates the...
Source: Current Cancer Drug Targets - July 23, 2018 Category: Cancer & Oncology Authors: Tran LNK, Kichenadasse G, Sykes PJ Tags: Curr Cancer Drug Targets Source Type: research

Linc01638 promotes tumorigenesis in HER2+ breast cancer.
In this study, linc01638 was found to be remarkably overexpressed in HER2-positive breast cancer cells and tissues. Suppression of linc01638 enhanced cell apoptosis, as well as inhibited the growth and invasiveness of HER2-positive breast cancer cells in vitro and tumor progression and metastasis in vivo. Furthermore, inhibition of linc01638 by shRNA attenuated expression of DNMT1, DNMT3a, and DNMT3b,and promoted expression of BRCA1 and PTEN in HER2-positive breast cancer cells and mouse xenograft models, indicating that linc01638 promoted tumorigenesis, partly by stimulating DNMTs signaling pathway and inhibiting expressi...
Source: Current Cancer Drug Targets - July 9, 2018 Category: Cancer & Oncology Authors: Liu P, Tang H, Wu J, Qiu X, Kong Y, Zhang L, Xie X, Xiao X Tags: Curr Cancer Drug Targets Source Type: research

Tumor-dependent effects of proteoglycans and various glycosaminoglycan synthesizing enzymes and sulfotransferases on patients' outcome.
CONCLUSIONS: A distinct association of BGN and DCN with CHST, CS polymerizing enzymes and DS epimerases was found in BC and glioma. Thus, a unique pattern of structural alterations and expression, which has clinical relevance, was found for PGs and GAG synthesizing enzymes and CHST in BC and glioma, which might help to identify high risk patients and to develop personalized therapeutics. PMID: 29984655 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - July 6, 2018 Category: Cancer & Oncology Authors: Subbarayan K, Seliger B Tags: Curr Cancer Drug Targets Source Type: research

Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Abstract Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which is an essential player in regulating cell migration, invasion, adhesion, proliferation, and survival. Its overexpression and activation have been identified in sixty-eight percent of epithelial ovarian cancer patients and this is significantly associated with higher tumor stage, metastasis, and shorter overall survival of these patients. Most recently, a new role has emerged for FAK in promoting resistance to taxane and platinum based therapy in ovarian and other cancers. The development of resistance is a complex network of molecular pr...
Source: Current Cancer Drug Targets - July 6, 2018 Category: Cancer & Oncology Authors: Levy A, Alhazzani K, Dondapati P, Alaseem A, Cheema K, Thallapureddy K, Kaur P, Alobid S, Rathinavelu A Tags: Curr Cancer Drug Targets Source Type: research

A Comprehensive review on Ethnomedicinal, Pharmacological and Phytochemical Basis of Anticancer Medicinal Plants of Pakistan.
Abstract The widespread emergence of cancer and development of resistance to chemotherapeutic agents is increasing the interest of scientists in the use of ethnomedicinal preparations and isolated phytochemicals in the treatment and prevention of disease. Medicinal plants are used in Pakistan for prehistoric times. The present review was designed to identify anticancer plants of ethnomedicinal significance and to summarize the anticancer activities carried out on these medicinal plants to establish the pharmacological and phytochemical basis for their use. Pakistani anticancer medicinal plants of ethnopharmacologi...
Source: Current Cancer Drug Targets - July 6, 2018 Category: Cancer & Oncology Authors: Akhtar MF, Saleem A, Yuchi A, Saleem M Tags: Curr Cancer Drug Targets Source Type: research

Conjugation of phthalocyanine photosensitizer with poly(amidoamine) dendrimer: improved solubility, disaggregation and photoactivity against HepG2 cells.
Conclusion:The conjugation of phthalocyanine photosensitizer ZnPcC4 to polyamidoamine dendrimer G3-PAMAM-NH2 officiously improved the PDT outcomes, in which the optimized binding ratio of ZnPcC4 to G3-PAMAM-NH2 was 6:1. PMID: 29984658 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - July 6, 2018 Category: Cancer & Oncology Authors: Jiang Z, Ye J, Yang J, Wang J, Jia L, Hoc RJ Tags: Curr Cancer Drug Targets Source Type: research

Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer.
Abstract Polyploidy is associated with increased cell size and commonly found in a subset of adult organs and blastomere stage of human embryo. The polyploidy is formed through endoreplication or cell fusion to support specific need of development including earliest embryogenesis. Recent data demonstrated that polyploid giant cancer cells (PGCCs) may have acquired an activated early embryonic-like program in response to oncogenic and therapeutic stress to generate reprogrammed cancer cells for drug resistance and metastasis. Targeting PGCCs may open up new opportunities for cancer therapy. PMID: 29968537 [Pub...
Source: Current Cancer Drug Targets - July 3, 2018 Category: Cancer & Oncology Authors: Chen J, Niu N, Zhang J, Qi L, Shen W, Donkena KV, Feng Z, Liu J Tags: Curr Cancer Drug Targets Source Type: research

Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality.
PMID: 29956604 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - July 1, 2018 Category: Cancer & Oncology Authors: Berretta M, Di Francia R Tags: Curr Cancer Drug Targets Source Type: research

Formulation, pharmacokinetic evaluation and cytotoxicity of an enhanced-penetration paclitaxel nanosuspension.
CONCLUSION: To sum up, our results showed that the optimal formula could improve the solubility of PTX and the stability of the product. The PTX-Nanos developed in this research would be a promising delivery platform in cancer treatment. PMID: 29956630 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - June 29, 2018 Category: Cancer & Oncology Authors: Cao Y, Wei Z, Li M, Wang H, Yin L, Chen D, Wang Y, Chen Y, Yuan Q, Pu X, Zong L, Duan S Tags: Curr Cancer Drug Targets Source Type: research

Interactions of vascular endothelial growth factor and p53 with miR-195 in thyroid carcinoma: possible therapeutic targets in aggressive thyroid cancers.
CONCLUSION: Our findings showed for the first time that miR-195 acts as a tumour suppressor and regulates cell cycle progression and apoptosis by targeting VEGF-A and p53 in thyroid carcinoma. The current study exhibited that miR-195 might represent a potential therapeutic target for patients with thyroid carcinomas having aggressive clinical behaviour. PMID: 29956628 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - June 28, 2018 Category: Cancer & Oncology Authors: Maroof H, Irani S, Ariana A, Vider J, Gopalan V, Lam AK Tags: Curr Cancer Drug Targets Source Type: research

Challenges and opportunities from basic cancer biology for nanomedicine for targeted drug delivery.
CONCLUSION: The information presented in this review can provide useful references for further studies on developing effective nanomedicine for treatment of cancer. PMID: 29956629 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - June 28, 2018 Category: Cancer & Oncology Authors: Xie X, Zhang Y, Li F, Lv T, Li Z, Chen H, Jia L, Gao Y Tags: Curr Cancer Drug Targets Source Type: research

Targeting Glycosylation Aberrations To Improve The Efficiency Of Cancer Phototherapy.
Abstract The use of photodynamic therapy in cancer still remains limited, partly because of the lack of photosensitizer (PS) specificity for the cancerous tissues. Various molecular tools are available to increase PS efficiency by targeting the cancer cell molecular alterations. The most strategies use the protein-protein interactions, e.g. monoclonal antibodies directed toward tumor antigens, such as HER2 or EGFR. An alternative could be the targeting of the tumor glycosylation aberrations, e.g. T/Tn antigens that are truncated O-glycans over-expressed in numerous tumors. Thus, to achieve an effective targeting, ...
Source: Current Cancer Drug Targets - June 27, 2018 Category: Cancer & Oncology Authors: Poiroux G, Barre A, Rouge P, Benoist H Tags: Curr Cancer Drug Targets Source Type: research

Macrophage flipping from foe to friend: A matter of interest in breast carcinoma heterogeneity driving drug resistance.
Abstract Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create interface with outside environment that lead to the unique identity of a specific cancer type. Among various contributors to tumor heterogeneity, cellular heterogeneity immensely plays a role in drug resistance and relapse of cancer. Within cellular heterogeneity of tumor, tumor-associated macrophages (TAMs) are pro-tumor type of immune cells that pr...
Source: Current Cancer Drug Targets - June 27, 2018 Category: Cancer & Oncology Authors: Tandon I, Sharma NK Tags: Curr Cancer Drug Targets Source Type: research

Malignant Intracranial High Grade Glioma and Current Treatment Strategy.
Abstract Malignant high grade glioma (HGG) is the most common and extremely fatal type of primary intracranial tumor. These tumors recurred within 2 to 3 cm of the primary region of tumor resection in the majority of cases. Furthermore, the blood-brain barrier significantly limited the access of many systemically administered chemotherapeutics to the tumor, pointing towards a stringent need for new therapeutic patterns. Therefore, targeting therapy using local drug delivery for HGG becomes a priority for the development of novel therapeutic strategies. The main objectives to the effective use of chemotherapy for H...
Source: Current Cancer Drug Targets - May 29, 2018 Category: Cancer & Oncology Authors: Zhang X, Zhang W, Mao XG, Cao WD, Zhen HN, Hu SJ Tags: Curr Cancer Drug Targets Source Type: research

Cellular Senescence-Inducing Small Molecules for Cancer Treatment.
CONCLUSION: To date, plenty of effective small-molecular chemotherapeutic drugs were exploited to evoke cellular senescence in cancer therapy through different mechanisms and pathways. Insight into the mechanisms and signaling pathways of these senescence-targeting chemotherapeutic drugs will facilitate the successful treatment of cancers in clinic. PMID: 29848278 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 29, 2018 Category: Cancer & Oncology Authors: Liu P, Wu Y, Lu Z, Shang D, Zhao Z, Shen Y, Zhang Y, Zhu F, Liu H, Tu Z Tags: Curr Cancer Drug Targets Source Type: research

Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
Abstract Local delivery of drug to the target organ via inhalation offers enormous benefits in the management of many diseases. Lung cancer is the most common of all cancers and it is the leading cause of death worldwide. Currently available treatment systems (intravenous or oral drug delivery) are not efficient in accumulating the delivered drug into the target tumor cells and are usually associated with various systemic and dose-related adverse effects. The pulmonary drug delivery technology would enable preferential accumulation of drug within the cancer cell and thus be superior to intravenous and oral deliver...
Source: Current Cancer Drug Targets - May 24, 2018 Category: Cancer & Oncology Authors: Islam N, Richard D Tags: Curr Cancer Drug Targets Source Type: research

Glycolysis inhibition as a strategy for hepatocellular carcinoma treatment?
Abstract Hepatocellular carcinoma (HCC) is the most frequently detected primary malignant liver tumor, representing a worldwide public health problem due to its high morbidity and mortality rates. The HCC is commonly detected in advanced stage, precluding the use of treatments with curative intent. For this reason, it is crucial to find effective therapies for HCC. Cancer cells have a high dependence of glycolysis for ATP production, especially under hypoxic environment. Such dependence provides a reliable possible strategy to specifically target cancer cells based on the inhibition of glycolysis. HCC, such as oth...
Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Alves A, Mamede AC, Alves M, Oliveira PF, Rocha SM, Botelho F, Maia CJ Tags: Curr Cancer Drug Targets Source Type: research

Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity in human pancreatic cancer cells.
CONCLUSION: Our findings demonstrated that IL-6 stimulates pancreatic cancer cell proliferation, survival and glycolysis, and supported persistent IL-6 signaling is a viable therapeutic target for pancreatic cancer using IL-6/GP130 inhibitors. PMID: 29714141 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Chen X, Tian J, Su GH, Lin J Tags: Curr Cancer Drug Targets Source Type: research

Efficacy and safety of antigen-specific immunotherapy in the treatment of patients with non-small-cell lung cancer: a systematic review and meta-analysis.
CONCLUSION: Our study demonstrated the clinical survival benefits of tecemotide and TG4010 in the treatment of NSCLC. However, these evidences might be limited by potential biases. Therefore, further well-conducted, large-scale RCTs are needed to verify our findings. PMID: 29714142 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Yan BD, Cong XF, Zhao SS, Ren M, Liu ZL, Li Z, Chen C, Yang L Tags: Curr Cancer Drug Targets Source Type: research

Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.
CONCLUSION: new perspectives emerge from the growing knowledge, bringing innovative techniques combining the action of Cxb with other substances or agents which act in a different way, but complementary, increasing the efficacy and minimizing toxicity. PMID: 29714143 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Quinones OG, Pierre MBR Tags: Curr Cancer Drug Targets Source Type: research

Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics.
Abstract Despite advances in the treatment regimen, the high incidence rate of breast cancer (BC) deaths is mostly caused by metastasis. Recently, the aberrant epigenetic modifications, which involve DNA methylation, histone modifications and microRNA (miRNA) regulations become attractive targets to treat metastatic breast cancer (MBC). In this review, the epigenetic alterations of DNA methylation, histone modifications and miRNA regulations in regulating MBC is discussed. The preclinical and clinical trials of epigenetic drugs such as the inhibitor of DNA methyltransferase (DNMTi) and the inhibitor of histone dea...
Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Wu YS, Lee ZY, Chuah LH, Mai CW, Ngai SC Tags: Curr Cancer Drug Targets Source Type: research

Biological activity of the novel vinca alkaloids 4-chlorochablastine und 4-chlorochacristine.
Abstract Vinca alkaloids are important cancer drugs belonging to the class of antimitotic agents. The most commonly used substances are vinblastine and vincristine, other compounds are vinorelbine and vinflunine. All of them are very effective drugs but their use is limited by severe side-effects including neurotoxicity and bone marrow depression. Therefore, it is very important to develop novel vinca alkaloids with similar efficacy but lower toxicity. Here, we analyzed two new compounds, 4-chlorochablastine and 4-chlorochacristine, with regard to their biological activity. These novel compounds were applied to a ...
Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Montag G, Stopper H, Ngo QA, Hintzsche H Tags: Curr Cancer Drug Targets Source Type: research

PRDM14: a potential target for cancer therapy.
Abstract PRDM14 belongs to PR domain-containing (PRDM) family. Although a precise understanding is focused on the function of PRDM14 maintains stemness and pluripotency in embryonic stem cells via epigenetic mechanisms, there are growing experimental evidences have been linked PRDM14 to human cancers. In adults, PRDM14 is low expression in human tissues. Aberrant PRDM14 expression is connected with various malignant histological types and solid cancers, where PRDM14 can act as a driver of oncogenic processes. Overexpression of RPDM14 enhanced cancer cells growth and reduced cancer cells sensitive to chemotherapeut...
Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Ou M, Li S, Tang L Tags: Curr Cancer Drug Targets Source Type: research

The Anti-malarial Drug Artesunate Blocks Wnt/ β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells.
CONCLUSION: Artesunate may be a potential interest for the therapy of uveal melanoma. PMID: 29692251 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 25, 2018 Category: Cancer & Oncology Authors: Zheng L, Pan J Tags: Curr Cancer Drug Targets Source Type: research

Interrupting the FGF19-FGFR4 axis to therapeutically disrupt cancer progression.
Abstract Coordination between amplification of the fibroblast growth factor FGF19, overexpression of its corresponding receptor FGFR4, and hyperactivation of the downstream transmembrane enzyme β-klotho have been found to play pivotal roles in mediating tumor development and progression. Aberrant FGF19-FGFR4 signaling has been implicated in driving specific tumorigenic events including cancer cell proliferation, apoptosis resistance, and metastasis by activating a myriad of downstream signaling cascades. As an attractive target, several strategies implemented to disrupt the FGF19-FGFR4 axis have been develope...
Source: Current Cancer Drug Targets - March 18, 2018 Category: Cancer & Oncology Authors: Lang L, Shull AY, Teng Y Tags: Curr Cancer Drug Targets Source Type: research

Preface.
PMID: 29517469 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 10, 2018 Category: Cancer & Oncology Authors: Zhang R Tags: Curr Cancer Drug Targets Source Type: research

Editorial: Cancer Epigenetics.
PMID: 29517470 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 10, 2018 Category: Cancer & Oncology Authors: Ahmad A Tags: Curr Cancer Drug Targets Source Type: research

Editorial: Oncolytic Virus and Gene Thearapy Application: Update 2018.
PMID: 29457568 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 21, 2018 Category: Cancer & Oncology Authors: Abei M Tags: Curr Cancer Drug Targets Source Type: research

SOCS6 functions as a tumor suppressor by inducing apoptosis and inhibiting angiogenesis in human prostate cancer.
Abstract Our previous studies revealed that the downregulation of Suppressor of cytokine signaling 6 (SOCS6) was correlated with malignant progression of human prostate cancer (PCa). In the current study, we aimed to investigate the tumor suppressive roles of SOCS6 and the underlying mechanisms in PCa. SOCS6 expression in PCa and non-cancerous prostate tissues were compared by immunohistochemistry. Statistical associations of SOCS6 expression with various clinicopathological features and patients' prognosis were evaluated. In addition, we investigated SOCS6's functions by overexpressing it in vitro (cell apoptosis...
Source: Current Cancer Drug Targets - January 1, 2018 Category: Cancer & Oncology Authors: Yuan D, Wang W, Su J, Zhang Y, Luan B, Rao H, Cheng T, Zhang W, Xiao S, Zhang M, Jiang FN, Sun Z, Jia Z, Zhong WD, Zhu J Tags: Curr Cancer Drug Targets Source Type: research

Novel homeodomain transcription factor Nkx2.2 in the brain tumor development.
CONCLUSION: Shh pathway play vital role in oligodendrocytes differentiation and Nkx2.2 transcription factor is essential for o ligodendrocytes differentiation and maturation. Intriguingly, down regulation of Nkx2.2 transcription factor with aberrant Shh signaling pathway is reported in glioma samples. So here suggest that Nkx2.2 expression pattern could be used as a potential biomarker for the early diagnosis of glioma. PMID: 29295693 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 1, 2018 Category: Cancer & Oncology Authors: Mariyath MP, Shahi MH, Farheen S, Tayyab M, Khanam N, Ali A Tags: Curr Cancer Drug Targets Source Type: research

Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications.
Abstract Testicular germ cell tumors (TGCTs) represent the most common malignancy in men aged 15-35. Due to these tumors' biological and clinical characteristics, they can serve as an appropriate system for studying molecular mechanisms associated with cisplatin-based treatment resistance. This review describes treatment resistance from clinical and molecular viewpoints. Cisplatin resistance is determined by various biological mechanisms, including the modulation of the DNA repair capacity of cancer cells, alterations to apoptotic cell death pathways, deregulation of gene expression pathways, epigenetic alteration...
Source: Current Cancer Drug Targets - January 1, 2018 Category: Cancer & Oncology Authors: Kalavska K, Conteduca V, De Giorgi U, Mego M Tags: Curr Cancer Drug Targets Source Type: research

Anticancer Properties of Essential Oils: an overview.
CONCLUSION: Several studies have demonstrated anti-carcinogenic and antitumor activity for many essential oils obtained from various plant species. They may be used in substitution to or in addition to conventional anti-cancer therapy. Although many studies report possible mechanisms of action for essential oils compounds, more studies are necessary in order to apply them safely and appropriately in cancer therapy. PMID: 29295695 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 1, 2018 Category: Cancer & Oncology Authors: Andrade MA, Braga MA, Cesar PHS, Trento MVC, Esposito MA, Silva LF Tags: Curr Cancer Drug Targets Source Type: research

Antibody based EpCAM targeted Therapy of Cancer, Review and update.
Abstract Todays, after four decades of the discovery of monoclonal antibodies by Kohler and Milstein in 1975, a dozen of antibodies are used in cancer targeted therapy with different strategies. The success of these antibodies depends on the specificity of antigens expressed on the cancer cells. Epithelial cell adhesion molecule (EpCAM), a homophilic cell-cell adhesion glycoprotein is a well- known tumor antigen, which expresses on epithelial tumors and circulating tumor cells as well as cancer stem cells. The EpCAM signaling pathway is associated with proliferation, differentiation and adhesion of epithelial canc...
Source: Current Cancer Drug Targets - January 1, 2018 Category: Cancer & Oncology Authors: Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M Tags: Curr Cancer Drug Targets Source Type: research

Towards prevention of ovarian cancer.
Abstract Ovarian cancer is the leading cause of death of all gynaecological cancers. To date, there is no reliable, specific screening procedure for detecting ovarian cancer. The risk factors of ovarian cancer include modifiable and non-modifiable factors. The main goal of the ovarian cancer prevention program is to significantly reduce the risk of development of ovarian cancer and other cancers such as breast and/or peritoneal cancer. The application of non-surgical preventive approaches such as oral contraceptives, parity and breastfeeding has been shown to be highly protective against ovarian cancer development...
Source: Current Cancer Drug Targets - January 1, 2018 Category: Cancer & Oncology Authors: Ali AT Tags: Curr Cancer Drug Targets Source Type: research

Targeting FGFR with BGJ398 in breast cancer: Effect on tumor growth and metastasis.
CONCLUSION: FGFR inhibitors are promising tools that require further investigation to identify sensitive tumors. These studies suggest that targeting FGFR combined with other targeted therapies will be useful to impair breast cancer progression. PMID: 29237381 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 13, 2017 Category: Cancer & Oncology Authors: Sahores A, May M, Sequeira G, Fuentes C, Jacobsen B, Lanari C, Lamb CA Tags: Curr Cancer Drug Targets Source Type: research

Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.
Abstract The effectiveness of new personalized treatment procedures in oncology is based on the fact that a certain tumor exhibits specific molecular features. More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usuallyinclude examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor. This review focuses on the pathologist's role in carefully co...
Source: Current Cancer Drug Targets - November 29, 2017 Category: Cancer & Oncology Authors: Alessandrini L, Perin T, Kadare S, Del Pup L, Memeo L, Steffan A, Colarossi L, Berretta M, De Paoli P, Canzonieri V Tags: Curr Cancer Drug Targets Source Type: research

Oncorine, the world first oncolytic virus medicine and its update in China.
Abstract The oncolytic viruses now hold a promise of new therapeutic strategy for cancer. Its concept has inspired a wave of commercial research and development activities for the products of this category in China since 1998. The first commercialized oncolytic virus product in the world, Oncorine (H101), developed by Shanghai Sunway Biotech Co., Ltd since 1999, was approved by Chinese SFDA in November, 2005 for nasopharyngeal carcinoma in combination with chemotherapy after the phase III clinical trial, and finally acquired GMP certificate in August, 2006. In this review, I will introduce how Oncorine was success...
Source: Current Cancer Drug Targets - November 29, 2017 Category: Cancer & Oncology Authors: Liang M Tags: Curr Cancer Drug Targets Source Type: research

Role of glioma-associated GLI1 oncogene in carcinogenesis and cancer-targeted therapy.
Abstract Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcinogenesis by inducing epithelial-mesenchymal transition (EMT), angiogenesis, and other signaling pathways. Overexpression of GLI1 is thought to be an indicator of poor prognosis as well as a potential therapeutic target for cancers. GLI inhibitors such as zerumbone, GANT61, resveratrol, and cy...
Source: Current Cancer Drug Targets - November 29, 2017 Category: Cancer & Oncology Authors: Wu J, Di D, Zhao C, Liu Y, Chen H, Gong Y, Zhao X, Chen H Tags: Curr Cancer Drug Targets Source Type: research

Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity.
This article discusses various mechanisms that have been proposed for the cardiotoxic effects of trastuzumab and the potential risk factors that can lead to cardiotoxicity. The recently approved anti-HER2 monoclonal antibodies including pertuzumab and ado-trastuzumab (T-DM1) are also discussed. PMID: 29189161 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 29, 2017 Category: Cancer & Oncology Authors: An J, Sheikh MS Tags: Curr Cancer Drug Targets Source Type: research

Tunneling nanotubes: A versatile target for cancer therapy.
Abstract Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) are common acute leukemia in adults and children respectively. In therapy process of these malignancies, chemotherapy is the main strategy that fails in many of cases. Moreover, chemotherapy is usually associated with adverse effects it also damages the healthy cells. In this regard, development of new therapies is essential. Monoclonal antibodies directed to the cell surface markers of leukemic blasts may have promising consequences. These tools can provide a specific cell targeting with minimal toxic effects on other normal cells. In this...
Source: Current Cancer Drug Targets - November 29, 2017 Category: Cancer & Oncology Authors: Sahoo P, Jena SR, Samanta L Tags: Curr Cancer Drug Targets Source Type: research

AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer.
CONCLUSION: Outcomes of CRPC patients are reported to be highly variable as consequence of tumor heterogeneity. AR CN could contribute to patient selection and tumor monitoring in CRPC treated with new anti-cancer treatment as abiraterone and enzalutamide. Further studies to investigate AR CN effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design. PMID: 29173173 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 22, 2017 Category: Cancer & Oncology Authors: Salvi S, Conteduca V, Lolli C, Testoni S, Casadio V, Zaccheroni A, Rossi L, Burgio SL, Menna C, Schepisi G, De Giorgi U Tags: Curr Cancer Drug Targets Source Type: research

A high-throughput quantitative expression analysis of cancer-related genes in human HepG2 cells in response to limonene, a potential anticancer agent.
CONCLUSION: The current study reveals that limonene could be a promising, cheap, and effective anticancer compound. The broad spectrum of limonene anticancer activity is interesting for anticancer drug development. Further research is needed to confirm the current findings and to examine the anticancer potential of limonene along with underlying mechanisms on different cell lines. PMID: 29141549 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 14, 2017 Category: Cancer & Oncology Authors: Hafidh RR, Hussein SZ, MalAllah MQ, Abdulamir AS, Abu Bakar F Tags: Curr Cancer Drug Targets Source Type: research

Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment.
Abstract One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor or hormone receptors. Many types of breast cancer exhibit different abnormalities in the apoptotic pathway, which confer the resistance to many forms of chemotherapy. Because of the fundamental importance of autophagy in the development and progression of cancer and its ability to affect trea...
Source: Current Cancer Drug Targets - November 14, 2017 Category: Cancer & Oncology Authors: Lisiak N, Toton E, Rybczynska M Tags: Curr Cancer Drug Targets Source Type: research

Editorial: Multiple Myeloma Immunotherapies.
PMID: 29117857 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 10, 2017 Category: Cancer & Oncology Authors: Podar K Tags: Curr Cancer Drug Targets Source Type: research

Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
Abstract Prostate cancer is the most common carcinoma among aged males in western countries and more aggressive and lethal castration resistant prostate cancer often occurs after androgen deprivation therapy. The high expression of androgens and androgen receptor is closely related to prostate cancer. Efficient androgen receptor antagonists, such as enzalutamide and ARN-509, could be employed as potent anti-prostate cancer agents. Nevertheless, recent studies have revealed that F876L mutation in androgen receptor converts the action of enzalutamide and ARN-509 from an antagonist to agonist, so that novel strategie...
Source: Current Cancer Drug Targets - November 6, 2017 Category: Cancer & Oncology Authors: Ge R, Xu X, Xu P, Li L, Li Z, Bian J Tags: Curr Cancer Drug Targets Source Type: research

Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
Abstract It has been reported that diallyl disulfide (DADS) has anti-proliferative activity in many cancers. The purpose of this study was to investigate the functions of DADS and the underlying mechanisms of its effect in breast cancer stem cells (BCSCs). Mammosphere formation assay, glucose consumption assay, lactate production assay and mouse xenograft experiments were performed to explore the functions of DADS in BCSCs. ATPase activity assay, western blotting and immunohistochemistry (IHC) assay were conduct to explore the mechanisms underlying the effects of DADS in BCSCs. The results showed that DADS suppres...
Source: Current Cancer Drug Targets - October 24, 2017 Category: Cancer & Oncology Authors: Xie X, Huang X, Tang H, Ye F, Yang L, Guo X, Tian Z, Peng C, Xie X Tags: Curr Cancer Drug Targets Source Type: research

Development In Drug Targeting And Delivery In Cervical Cancer.
Abstract Cervical cancer is the second most common cancer in women. Standard treatment options available for cervical cancer including chemotherapy, surgery and radiation therapy associated with their own side effects and toxicities. Tumor-targeted delivery of anticancer drugs is perhaps one of the most appropriate strategies to achieve optimal outcomes from treatment and improve quality of life. Recently nanocarriers based drug delivery systems owing to their unique properties have been extensively investigated for anticancer drug delivery. In addition to that addressing the anatomical significance of cervical ca...
Source: Current Cancer Drug Targets - October 9, 2017 Category: Cancer & Oncology Authors: Aggarwal U, Goyal AK, Rath G Tags: Curr Cancer Drug Targets Source Type: research